Pelareorep combined with standard chemotherapy achieved a 33% objective response rate in KRAS-mutant MSS mCRC, surpassing ...
HER2CLIMB-05 successfully met its primary endpoint of progression-free survival (PFS), with the addition of tucatinib ...
Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key ...
Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, ...
Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...
Maen Abdelrahim, MD, PhD, Section Chief of Gastrointestinal Medical Oncology at Houston Methodist Neal Cancer Center in Texas ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...
The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment. ...
PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback